Bone marrow necrosis following treatment for chronic myeloid leukaemia with STI-571
Field | Value | Language |
dc.contributor.author | Burton, C | |
dc.contributor.author | Azzi, A | |
dc.contributor.author | Kerridge, I | |
dc.date.accessioned | 2014-06-23 | |
dc.date.available | 2014-06-23 | |
dc.date.issued | 2002-01-01 | |
dc.identifier.citation | Burton C, Azzi A, Kerridge I H. Bone marrow necrosis following treatment for chronic myeloid leukaemia with STI-571. N Engl J Med; 2002; 346(9):713. | en_AU |
dc.identifier.uri | http://hdl.handle.net/2123/10811 | |
dc.description.abstract | Imatinib mesylate has recently been licensed for the treatment of selected patients with chronic myelogenous leukemia (CML). 1We report a case of bone marrow necrosis secondary to imatinib mesylate therapy in a patient with accelerated-phase CML | en_AU |
dc.language.iso | en_AU | en_AU |
dc.publisher | Massachusetts Medical Society | en_AU |
dc.title | Bone marrow necrosis following treatment for chronic myeloid leukaemia with STI-571 | en_AU |
dc.type | Article, Letter | en_AU |
dc.type.pubtype | Publisher version | en_AU |
Associated file/s
Associated collections